Ultragenyx Pharmaceutical Inc. reports results for the quarter ended September 30 - Earnings Summary

What happened

Ultragenyx Pharmaceutical Inc. reported an adjusted loss of $1.16 per share for the quarter ended September 30, compared with a larger adjusted loss per share in the same quarter last year. Revenue rose 8.2% to $173.00 million, below analysts’ expectation of $183.12 million, and the company reported a quarterly loss of $118 million.

Confirmed

Global impact / market context

Revenue growth shows sales increased, but the shortfall against analysts’ forecast and the larger adjusted loss per share could weaken confidence in the company’s ability to turn sales into profits. If that gap persists, pressure to control costs or secure more cash could increase.

Analyst inference

Analysts had lowered their average earnings estimate by about 5.6% over three months, and two revised estimates down in the last 30 days. Despite this, the average rating remained “buy”; the article reports shares were down 29.1% year to date.

Confirmed

What to watch

1. Future quarterly revenue and losses will show whether sales growth can narrow the earnings gap and bring results closer to analyst expectations. Analyst inference
2. Further analyst estimate revisions and rating changes could affect investor expectations, especially if revenue continues to fall short of forecasts. Analyst inference
3. The company’s next results may clarify whether its reported sales growth is translating into improved earnings or a smaller total loss. Analyst inference

Evidence

• Original source link unavailable